Adjunctive Medication for Schizophrenia with Comorbid Panic Disorder and GAD
For a patient with schizophrenia on aripiprazole who has comorbid panic attacks and GAD, add an SSRI (specifically paroxetine or sertraline) as first-line pharmacotherapy for the anxiety disorders, while continuing the aripiprazole for schizophrenia management. 1, 2
Rationale for SSRI Selection
SSRIs are FDA-approved for both panic disorder and GAD, making them the evidence-based choice for this dual anxiety presentation. 1
- Paroxetine is FDA-approved for panic disorder, GAD, and social anxiety disorder, providing broad-spectrum anxiety coverage 1
- Sertraline is well-tolerated and has less effect on metabolism of other medications compared to other SSRIs, which is advantageous when combined with aripiprazole 3
- Start paroxetine at 10 mg daily (maximum 40 mg daily) or sertraline at 25-50 mg daily (maximum 200 mg daily) 3
- Allow 4-8 weeks for full therapeutic effect before determining efficacy 3
Why Continue Aripiprazole
The APA strongly recommends (1A) that patients with schizophrenia whose symptoms have improved with an antipsychotic medication continue treatment with that antipsychotic. 2
- Discontinuing antipsychotic medication significantly increases relapse risk, with 70% of patients requiring long-term medication to control symptoms 4
- Switching from stable antipsychotic therapy is associated with significant risk of treatment discontinuation (risk ratio 2.28) and symptom worsening 4
- Aripiprazole has demonstrated efficacy for both positive and negative symptoms of schizophrenia and is well-tolerated 5, 6
Alternative Considerations
If SSRI Response is Inadequate After 4-8 Weeks:
Consider adding low-dose benzodiazepines for acute panic symptoms, though this should be time-limited due to dependence risk 3:
- Lorazepam, oxazepam, or temazepam (short half-life agents are least problematic) 3
- Use only for breakthrough symptoms, not as primary treatment
Atypical Antipsychotic Augmentation (Less Preferred):
While quetiapine has the most evidence for GAD among atypical antipsychotics, approximately 50% of patients discontinue due to sedation and fatigue, making it a less favorable option 7. Additionally:
- Antipsychotic polypharmacy should generally be avoided as initial strategy to minimize side effects 2, 8
- The APA recommends antipsychotic monotherapy as first-line treatment 9
Monitoring Requirements
Regular monitoring is essential when combining medications:
- Monitor for serotonin syndrome when combining SSRIs with other serotonergic agents 1
- Assess for extrapyramidal symptoms with aripiprazole, documenting baseline abnormal movements 8
- Monitor metabolic parameters including BMI, waist circumference, blood pressure, HbA1c, glucose, and lipids 4
- Reassess anxiety symptoms at 4-8 weeks to determine SSRI efficacy 3
Critical Pitfalls to Avoid
Do not discontinue or reduce aripiprazole to "make room" for anxiety medication - this significantly increases psychotic relapse risk 2, 4
Do not use atypical antipsychotics as first-line treatment for GAD/panic disorder when FDA-approved options (SSRIs) are available and appropriate 1, 7
Do not expect immediate anxiety relief - SSRIs require 4-8 weeks for full therapeutic effect, and patients need counseling about this timeline 3
Avoid fluoxetine initially due to its very long half-life and activating properties, which may worsen anxiety symptoms in the short term 3